Session: MP29: Prostate Cancer: Advanced (including Drug Therapy) II
MP29-18: Oncological outcomes in the metastatic low tumor-burden prostate cancer are not significantly different from the locally advanced (T4 or N1) prostate cancer
Introduction: The difference in oncological outcomes between patients with locally advanced (T4 or N+) prostate cancer and metastatic prostate cancer with low tumor-burden disease remain unclear. We retrospectively compared the oncological outcomes between the locally advanced disease (M0-advanced group) and metastatic low-burden disease (M1-low group). Methods: We evaluated 186 and 319 patients with the M0-advanced and M1-low groups treated with androgen deprivation therapy alone. Castration-resistant prostate cancer (CRPC)-free survival and overall survival were compared by a multivariable Cox regression analysis using inverse probability of treatment weighting method. We also evaluated risk factors for poor prognosis. Results: Of 505, 138 (27.3%) patients underwent local interventions (surgery or radiotherapy). We observed no significant difference in CRPC-free survival and overall survival between the M0-advanced and M1-low groups. Multivariable Cox regression analysis showed that a Gleason score 9-10, T4 or N1 status, and no local intervention were significantly associated with poor prognosis. Local interventions are background difference for local intervention between the groups. Conclusions: Oncological outcomes of the groupM1-low group were not significantly different from the M0-advanced. Gleason score, locally advanced status (T4 or N1), and local intervention potentially associate with oncological outcomes. SOURCE OF Funding: none
